Thank you very much, Mr. Chair.
I'd like to thank the witnesses who have joined us to contribute to the study.
I'll begin with some questions for Ms. Beauger.
Ms. Beauger, It's a pleasure to welcome you to the committee today in connection with this important study.
Of course, I congratulate you on your commitment to IRICoR. I know that you worked there for quite a few years and that you now appear to be headed towards new challenges. I did nevertheless want to draw attention to your excellent work and point out that we can take pride in having an organization like IRICoR in Quebec. It is having a major impact on the transformative research being conducted in Quebec, elsewhere in Canada, and around the world, on highly innovative therapeutic solutions.
I'm going to follow up on my colleague's line of questioning. I'd like to know more about the status of the situation in Canada and where it stands in the commercialization of intellectual property.
According to the most recent data from Innovation, Science and Economic Development Canada, which happens to be from 2016, Canada was ranked 31st out of 37 OECD countries in terms of trademark applications per capita.
Do you have anything to say about that?